Cargando…

Candidate Urine Peptide Biomarkers for IgA Nephropathy: Where Are We Now?

Early detection, prognosis, and management of IgA nephropathy (IgAN) remain a challenge. Histological examination of renal tissue still comprises the only way to confirm an IgAN diagnosis. It is of great importance to establish noninvasive diagnostic, prognostic, and predictive biomarkers that would...

Descripción completa

Detalles Bibliográficos
Autores principales:	Marek-Bukowiec, Karolina, Konieczny, Andrzej, Ratajczyk, Krzysztof, Witkiewicz, Wojciech
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2018
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5827886/ https://www.ncbi.nlm.nih.gov/pubmed/29606986 http://dx.doi.org/10.1155/2018/5205831

Ejemplares similares

The Clinical Significance of Urinary Retinol-Binding Protein 4: A Review
por: Ratajczyk, Krzysztof, et al.
Publicado: (2022)

Secondary IgA Nephropathy and IgA-Associated Nephropathy: A Systematic Review of Case Reports
por: Tota, Maciej, et al.
Publicado: (2023)

The Non-Coding RNA Landscape in IgA Nephropathy—Where Are We in 2021?
por: Pawluczyk, Izabella Z. A., et al.
Publicado: (2021)

Clinical and Histopathological Factors Influencing IgA Nephropathy Outcome
por: Konieczny, Andrzej, et al.
Publicado: (2021)

Machine Learning in Prediction of IgA Nephropathy Outcome: A Comparative Approach
por: Konieczny, Andrzej, et al.
Publicado: (2021)

Galactose-Deficient IgA1 as a Candidate Urinary Marker of IgA Nephropathy
por: Fukao, Yusuke, et al.
Publicado: (2022)

Galactose-Deficient IgA1 as a Candidate Urinary Polypeptide Marker of IgA Nephropathy?
por: Suzuki, Hitoshi, et al.
Publicado: (2016)

Urine proteomics for prediction of disease progression in patients with IgA nephropathy
por: Rudnicki, Michael, et al.
Publicado: (2020)

Aberrantly Glycosylated IgA1 in IgA Nephropathy: What We Know and What We Don’t Know
por: Ohyama, Yukako, et al.
Publicado: (2021)

Where are we now and where are we headed?
por: Langan, Ewan A.
Publicado: (2023)

The Role of IgA in the Pathogenesis of IgA Nephropathy
por: Perše, Martina, et al.
Publicado: (2019)

Where are we now?
Publicado: (1977)

Radiologic approach to axial spondyloarthritis: where are we now and where are we heading?
por: Kucybała, Iwona, et al.
Publicado: (2018)

Dynamics of urine proteomics biomarker and disease progression in patients with IgA nephropathy
por: Peters, Björn, et al.
Publicado: (2023)

IgA Vasculitis and IgA Nephropathy: Same Disease?
por: Pillebout, Evangeline
Publicado: (2021)

IgA nephropathy associated with coeliac disease
por: Habura, Ireneusz, et al.
Publicado: (2019)

Experimental IgA nephropathy
Publicado: (1979)

Sulodexide in IgA nephropathy
Publicado: (2013)

T lymphocytes in IgA nephropathy
por: Tang, Yuyan, et al.
Publicado: (2020)

NIPPV: Where Are We Now?
por: Fakharian, Atefeh, et al.
Publicado: (2013)

Onchodermatitis: Where Are We Now?
por: Murdoch, Michele E.
Publicado: (2018)

Secondary IgA Nephropathy Shares the Same Immune Features With Primary IgA Nephropathy
por: Wang, Manliu, et al.
Publicado: (2019)

Validation of the International IgA Nephropathy Prediction Tool in the Greek Registry of IgA Nephropathy
por: Papasotiriou, Marios, et al.
Publicado: (2022)

AI in medicine: Where are we now and where are we going?
por: Shandhi, Md Mobashir Hasan, et al.
Publicado: (2022)

Intrahepatic Cholangiocarcinoma—Where Are We Now and Where Are We Going to?
por: Wasilewicz, Michał P., et al.
Publicado: (2023)

Current understanding of IgA antibodies in the pathogenesis of IgA nephropathy
por: Nihei, Yoshihito, et al.
Publicado: (2023)

The Brain-gut Axis-where are we now and how can we Modulate these Connections?
por: Dabrowski, Wojciech, et al.
Publicado: (2021)

Detection of Podocin in Human Urine Sediment Samples by Charge Derivatization and LC-MS-MRM Method
por: Bąchor, Remigiusz, et al.
Publicado: (2020)

IgA Nephropathy Genetic Risk Score to Estimate the Prevalence of IgA Nephropathy in UK Biobank
por: Sukcharoen, Kittiya, et al.
Publicado: (2020)

Serum and Urine Biomarkers Related to Kidney Fibrosis Predict Kidney Outcome in Czech Patients with IgA Nephropathy
por: Neprasova, Michaela, et al.
Publicado: (2023)

Vesicoureteral Reflux: Where Have We Been, Where Are We Now, and Where Are We Going?
por: McLorie, Gordon A.
Publicado: (2008)

Platelet-Rich Plasma: Where Are We Now and Where Are We Going?
por: Cole, Brian J., et al.
Publicado: (2010)

Aging with Down Syndrome—Where Are We Now and Where Are We Going?
por: Alldred, Melissa J., et al.
Publicado: (2021)

Immunotherapies in Genitourinary Oncology: Where Are We Now? Where Are We Going?
por: Jang, Albert, et al.
Publicado: (2021)

Ten Years for GHSP: Where Are We Now? Where Will We Go?
por: Bhutta, Zulfiqar A., et al.
Publicado: (2023)

Targeting therapy in pemphigus: Where are we now and where are we going?
por: Abulikemu, Kailibinuer, et al.
Publicado: (2023)

CAR-T cell therapy: Where are we now, and where are we heading?
por: Wang, Jia-Yi, et al.
Publicado: (2023)

Thrombotic Microangiopathy in IgA Nephropathy
por: Nasri, Hamid
Publicado: (2013)

Role of complement in IgA nephropathy
por: Daha, Mohamed R., et al.
Publicado: (2015)

Nutcracker phenomenon in IgA nephropathy
por: Imai, Naohiko, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_0r7egtg1fuc0d2ln42gp2cch37